Novel scaffold for cathepsin K inhibitors.
Teno, N., Miyake, T., Ehara, T., Irie, O., Sakaki, J., Ohmori, O., Gunji, H., Matsuura, N., Masuya, K., Hitomi, Y., Nonomura, K., Horiuchi, M., Gohda, K., Iwasaki, A., Umemura, I., Tada, S., Kometani, M., Iwasaki, G., Cowan-Jacob, S.W., Missbach, M., Lattmann, R., Betschart, C.(2007) Bioorg Med Chem Lett 17: 6096-6100
- PubMed: 17911019 
- DOI: https://doi.org/10.1016/j.bmcl.2007.09.047
- Primary Citation of Related Structures:  
2R6N - PubMed Abstract: 
Pyrrolopyrimidine, a novel scaffold, allows to adjust interactions within the S3 subsite of cathepsin K. The core intermediate 10 facilitated the P3 optimization and identified highly potent and selective cathepsin K inhibitors 11-20.
Organizational Affiliation: 
Novartis Institutes for BioMedical Research, Ohkubo 8, Tsukuba, Ibaraki, Japan. naoki.teno@novartis.com